# OnCo record paper-nct04854668-signal-transduct-target-ther-2026 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct04854668-signal-transduct-target-ther-2026/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct04854668-signal-transduct-target-ther-2026" ;
  schema:name "First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial"@en ;
  schema:description "Published report from the BRAF Wild Metastatic Colorectal Can trial registered as NCT04854668, in Signal transduction and targeted therapy (2026), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct04854668-signal-transduct-target-ther-2026/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41392-026-02938-4>, <https://pubmed.ncbi.nlm.nih.gov/42675036/>, <https://europepmc.org/article/MED/42675036>, <https://clinicaltrials.gov/study/NCT04854668> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1038/s41392-026-02938-4> ;
  schema:datePublished "2026"^^xsd:gYear ;
  schema:author "Liu Y, Zhang Y, Lin R, et al." ;
  onco:trials <https://onco.cc/trials/nct04854668/> .